Market Overview

My goal is to be on stage with my computer and let you
see my screen and make sure you know what buttons to
press, where you’re getting in & out, how to calculate
risk, your targets — all of those things.
It’s real-life trading. Make sure you sign up!
- Jerremy Newsome
GET TICKETS

UPDATE: Stifel Terminates Coverage on Onyx Pharmaceuticals Following Acquisition by Amgen

Share:

In a report published Friday, Stifel analyst Stephen Willey terminated coverage on Onyx Pharmaceuticals (NASDAQ: ONXX).

In the report, Stifel noted, “We are discontinuing coverage of Onyx Pharmaceuticals due to the company's acquisition by Amgen (AMGN, Covered by our Colleague Joel Sendek, Hold, $115.41) at $125.00 per share in cash. Our last rating on the stock was Hold. Our FY13 estimates for ONXX were EPS of $(2.92) and $626M of revenues.”

Onyx Pharmaceuticals closed on Thursday at $124.70.

Latest Ratings for ONXX

DateFirmActionFromTo
Nov 2013Terminates
Aug 2013DowngradesBuyHold
Aug 2013DowngradesBuyNeutral

View More Analyst Ratings for ONXX
View the Latest Analyst Ratings

Posted-In: Stephen Willey StifelAnalyst Color Termination Analyst Ratings

 

Related Articles (ONXX)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
BSXMaintains45.0
CLMaintains68.0
HPMaintains75.0
KMBMaintains145.0
AMNMaintains60.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

UPDATE: Deutsche Bank Downgrades Prudential Financial on Valuation

UPDATE: Stifel Reiterates on Conatus Pharmaceuticals on HCV-POLT Strategy Shift